These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28579726)

  • 1. Inpatient Antineoplastic Medication Administration And Associated Drug Costs: Institution of a Hospital Policy Limiting Inpatient Administration.
    Foster AE; Reeves DJ
    P T; 2017 Jun; 42(6):388-393. PubMed ID: 28579726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring Cost Savings with Specialty Biologic Drugs Administered to Adult Inpatients with Inflammatory Bowel Disease.
    Pitman S; Jones C; Polyak S; Taylor A; Cerven-Jenn D; Reist D
    Hosp Pharm; 2022 Feb; 57(1):112-116. PubMed ID: 35521007
    [No Abstract]   [Full Text] [Related]  

  • 3. Implementation of a chemotherapy stewardship process.
    Hennes ER; Reed M; Mably M; Jared J; Bergsbaken JJ; Deming D; Callander N; O'Regan R
    Am J Health Syst Pharm; 2020 Jul; 77(15):1243-1248. PubMed ID: 32620961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Cost Comparison Evaluation of Inpatient Versus Outpatient Administration of EPOCH-Containing Regimens in Non-Hodgkin Lymphoma.
    Evans SS; Gandhi AS; Clemmons AB; DeRemer DL
    J Pharm Pract; 2017 Aug; 30(4):400-405. PubMed ID: 27432462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making moves: Transitioning R-EPOCH to the ambulatory setting.
    Martin AL; Frank JP; Waggoner ML
    J Oncol Pharm Pract; 2018 Dec; 24(8):617-622. PubMed ID: 28782408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Inpatient Administration of Restricted Antineoplastic Medications at a Large Academic Medical Institution.
    Lau KM; Derry K; Dalton A; Martino J
    P T; 2019 Aug; 44(8):481-496. PubMed ID: 31447536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy for colon cancer--analysis of treatment costs from the perspective of statutory sickness funds.
    Görner M; Riemer-Hommel P
    Z Gastroenterol; 2008 Jul; 46(7):681-8. PubMed ID: 18618379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC; Marcoux RM; Quilliam BJ
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing Hospitalizations: Institution of Outpatient Infusional EPOCH-Based Chemotherapy at a Safety Net Hospital.
    Keshvani N; Hon M; Gupta A; Brown TJ; Roy L; Marley E; Lindsey S; Johnson DH; Sadeghi N; Li HC
    J Oncol Pract; 2019 Aug; 15(8):e644-e651. PubMed ID: 31206340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.
    Sikand H; Decter A; Greco T; Watson SH; Kang YJ; Mody SH; Piech CT; Duh MS; Naeem A
    Ann Pharmacother; 2008 Jan; 42(1):16-23. PubMed ID: 18029428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential cost savings by dose down-rounding of monoclonal antibodies in a community cancer center.
    Copur MS; Gnewuch C; Schriner M; Tharnish M; Gonen M; McDonald M; Kezeor J; Ramaekers RC; Gauchan D; Clark D; Greenwalt L; Mickey M; Norvell M
    J Oncol Pharm Pract; 2018 Mar; 24(2):116-120. PubMed ID: 29284380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
    Vaughn JE; Othus M; Powell MA; Gardner KM; Rizzuto DL; Hendrie PC; Becker PS; Pottinger PS; Estey EH; Walter RB
    JAMA Oncol; 2015 Nov; 1(8):1120-7. PubMed ID: 26355382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS.
    Hirsch JD; Gonzales M; Rosenquist A; Miller TA; Gilmer TP; Best BM
    J Manag Care Pharm; 2011 Apr; 17(3):213-23. PubMed ID: 21434698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospital cost containment in the 1980s. Hard lessons learned and prospects for the 1990s.
    Schwartz WB; Mendelson DN
    N Engl J Med; 1991 Apr; 324(15):1037-42. PubMed ID: 2005941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong.
    Zhou KR; Cheng A; Ng WT; Kwok TY; Yip EY; Yao R; Leung PY; Lee VW
    J Med Econ; 2017 May; 20(5):541-548. PubMed ID: 28277030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer.
    Seal BS; Anderson S; Shermock KM
    J Manag Care Spec Pharm; 2016 Mar; 22(3):227-35. PubMed ID: 27003552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
    Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.